Qiagen N.V. (QGEN)

Market Cap	11.17B
Revenue (ttm)	2.07B
Net Income (ttm)	405.37M
Shares Out	206.00M
EPS (ttm)	1.94
PE Ratio	28.65
Forward PE	21.51
Dividend	$2.41 (4.43%)
Ex-Dividend Date	Jan 8, 2026

Volume	5,750,721
Open	54.11
Previous Close	55.45
Day's Range	53.75 - 55.61
52-Week Range	39.61 - 57.82
Beta	0.66
Analysts	Buy
Price Target	47.81 (-11.81%)
Earnings Date	Feb 4, 2026

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Analyst Summary

According to 6 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $47.81, which is a decrease of -11.81% from the latest price.

Price Target

$47.81

(-11.81% downside)

Analyst Consensus: Buy